

The importance of patient education, patient-physician interaction and ultimately shared decision-making when tailoring HAE treatment

Dr. Danny Cohn


Angioedema Center of Reference and Excellence (ACARE)
Department of Vascular Medicine
Amsterdam UMC, The University of Amsterdam
Amsterdam, Netherlands



Why is this topic important?

On-demand only
Prophylaxis
Administration
Side effects
Interactions
Availability
Scientific evidence

Experiences
Expectations
Preferences
Assumptions
Hobbies
Lifestyle



Doctor

Patient

What does the science say?

2019 International/Canadian guideline¹

“The decision to start or stop LTP should be made **jointly by the patient and an HAE specialist. The patient needs to be informed** of the risk and benefits of all therapies [...] to enable making an **informed decision.**”

2020 US HAEA guideline²

“HAE management plans must be **individualized to each patients needs** due to wide variability in HAE symptoms, response to and tolerance of various HAE medications, and numerous factors impacting clinical course and quality of life. Treatment plans should be **monitored regularly and adjusted based on the needs of the patient.**”

2021 Global Delphi Initiative³

“[...] the importance of taking **a holistic, patient-centered, shared decision-making approach when assessing control of HAE**; shared decision-making is proposed to have several benefits including improved disease management, better outcomes and treatment adherence, and reduced costs.”

HAE, hereditary angioedema; IV, intravenous; LTP, long-term prophylaxis; US HAEA, US Hereditary Angioedema Association.

1. Betshel *et al. Allergy, Asthma Clin Immunol.* 2019;15(72) 2. Busse *et al. J Allergy Clin Immunol Pract.* 2021;9(1):132-150.e3;

3. Maurer *et al. J Allergy Clin Immunol.* 2021;25:S0091-6749(21)00821-6.

The importance of patient education, patient-physician interaction and ultimately shared decision-making when tailoring HAE treatment

1. Explore the patient's expectations/preferences/disease control

2. Weigh various available options and discuss pros and cons

3. Discuss re-evaluation time points

4. If no solution is optimal: think harder!

- Trials
- Early access / compassionate use
- Think out-of-the-box ^{1,2,3}